Non-nuberculous mycobacteria infection treated with intermittently inhaled high-dose nitric oxide

Aviv Goldbart, Dvir Gatt, Inbal Golan Tripto

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Mycobacterium abscessus is an emerging multidrug-resistant non-tuberculous mycobacterium (NTM) with high prevalence in patients with cystic fibrosis. However, studies on antimicrobial susceptibilities and effective treatments against M. abscessus are still limited. Nitric oxide (NO) is important in innate immune response to various infections, including mycobacterial infections. In this case study, we describe a compassionate treatment of inhaled NO (iNO) at 150-250 ppm for 4 weeks. The dosing strategy proposed for this treatment was selected to minimise the potential of adverse events, while maximising the antibacterial effectiveness of NO, and was found to be safe, well tolerated and resulted in positive clinical findings including improvement in patient well-being, CT scan values, quality of life and bacterial load. Taken together, these observations may indicate that iNO could play a crucial role and potentially serve as a reliable option in the treatment of patients with chronic refractory NTM lung infection.

Original languageEnglish
JournalBMJ Case Reports
Issue number10
StatePublished - 28 Oct 2021
Externally publishedYes


  • cystic fibrosis
  • respiratory medicine

ASJC Scopus subject areas

  • Medicine (all)


Dive into the research topics of 'Non-nuberculous mycobacteria infection treated with intermittently inhaled high-dose nitric oxide'. Together they form a unique fingerprint.

Cite this